AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40 mg administered via subcutaneous injection once every two weeks
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally
Study NCT02889796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally
Study NCT01394081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement and Enrollment (EEE)
Description: Consists of motivational interviewing, educational outreach, and patient navigation.
Study NCT01394081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administrative Outreach (AO)
Description: Consists of giving information about enrolling for VA medical care or scheduling an appointment
Study NCT02814565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine HCl
Description: Cyclobenzaprine HCl extended-release capsules
Study NCT02814565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cyclobenzaprine HCl extended release placebo-matching capsules
Study NCT05815589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw retained prosthesis group
Description: hybrid prosthesis screwed on four mandibular intra-foraminal implants
Study NCT05815589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screw retained prosthesis group
Description: hybrid prosthesis screwed on four mandibular intra-foraminal implants
Study NCT04644809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3561774
Description: Administered SC.
Study NCT04644809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT04639622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Investigation procedures
Description: All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
Study NCT01312597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice beverage
Description: 500ml fruit juice beverage, single dose per visit
Study NCT04230174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PBR28
Description: This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
Study NCT03156400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Stress Test
Description: Gradual increase in treadmill grade while collecting respiratory gases.
Study NCT04677712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCH-aaes
Description: Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
Study NCT04677712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression
Description: Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections.
Study NCT04677712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Packs
Description: Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections.
Study NCT04677712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica Gel
Description: Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.
Study NCT04677712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INhance®
Description: Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
Study NCT04677712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDL
Description: Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection.
Study NCT04563429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Vitamin A
Description: Oral administration of 5000 EU of Vitamin A during first 28 days of life
Study NCT01659645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
Study NCT01065688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en Y reconstruction
Description: surgical procedure
Study NCT01065688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Billroth-I reconstruction
Description: surgical procedure
Study NCT02290795 — intervention group
Intervention type: OTHER
Intervention: OCT imaging/HRT imaging
Description: Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
Study NCT03627845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-303
Description: Investigational drug
Study NCT03627845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01070160 — intervention group
Intervention type: DRUG
Intervention: Endometrin (progesterone 100mg vaginal inserts)
Description: once a day, 6-8 days as specified (prior to each EMBx)
Study NCT01070160 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: per clinical care guidelines
Study NCT02118688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT02118688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Study NCT02118688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02118688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02113735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar® Gel (repository corticotropin injection)
Study NCT02113735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05459623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual myofascial release
Description: will receive Manual myofascial release to iliotibial band by having the subject to lie in the side lying position on the unaffected side. The upper leg to be tested was rested on the table with hip and knee flexion. Then the therapist applied a few kilograms of force weight along the iliotibial band course proximally to distally. The therapist will repeat this for 6 minutes.
Study NCT05459623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emmett intervention
Description: will receive manual myofascial release and the Emmett intervention with the subject sitting upright on a 45cm wooden chair; light, constant pressure via the middle finger (at a perpendicular angle to the skin) will be applied at both points, three times for 10-20s with 5-10s breaks between. A light sweeping action over the sensory area that will treated will be performed once, using the back of the fingers. The rationale for this is that the light brushing action disperses the sensory awareness to move without being too heavy or specific enough to create muscular response. The sequence performed on one side will then repeated on the opposite leg. In Ross Emmett's teachings of the technique he insists on treatment of both sides when focusing on the lower body (for balance). Once both sides will be completed, the subject will be instructed to walk around the room for a minute.
Study NCT02988765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Groin ultrasound +/- fine needle aspiration
Description: Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound
Study NCT01476657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145 (duvelisib)
Description: Oral Twice A Day (BID) Dosing
Study NCT00928538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced NFP Care
Description: Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
Study NCT04377451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing \<60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg
Study NCT02188030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise Program
Description: The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
Study NCT02188030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Exercise Program
Description: The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
Study NCT02585011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02585011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study NCT02585011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02281695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP adjusment during the Weaning process
Description: The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
Study NCT01356914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 10 mg, Every Day (QD), 20 days
Study NCT01356914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
Study NCT01356914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914392
Description: Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
Study NCT01356914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
Study NCT02796378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Training+Simvastatin+Q10-placebo
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
Study NCT02796378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Training+Simvastatin-placebo+Q10-placebo
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
Study NCT02796378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Training+Simvastatin+Q10
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
Study NCT03534700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parasacral flap reconstruction
Description: parasacral flap reconstruction
Study NCT03534700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open excision
Description: open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
Study NCT02387359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plecanatide
Study NCT02387359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04466800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group_rehabilitation program
Description: Regular physical activity, supervised by a physical education educator, a systematic malnutrition screening and a nutritional follow-up performed by a dietetician.~Patients will follow a 4-week rehabilitation program, comprising 3 physical activity sessions per week for 4 weeks. First sessions will be supervised by a physical activity educator and patients will perform the following sessions at home, using physical training software. The physical activity educator will call patients once a week to ensure the sessions are correctly performed and adapt the program if necessary. Patients will also undergo a nutritional assessment carried out by a dietitian at the beginning of the program. A dietitian will call patients once a week to ensure their nutritional status is appropriate.
Study NCT01692548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study NCT03245450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate
Description: IV infusion
Study NCT03245450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: IV infusion
Study NCT00513032 — intervention group
Intervention type: DRUG
Intervention: methylene blue
Description: 5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
Study NCT01870154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
Study NCT01870154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
Study NCT03283176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin B12 and Folic Acid
Description: Vitamin B12 and Folic Acid measurement by ELISA technique
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 (Lipitor®)
Description: atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 (Ezetrol®)
Description: After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT03553823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsies
Description: At Baseline, two 6-mm punch biopsies were taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy was taken from the same area of the active plaque sampled at Baseline.
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 (Lipitor®, Ezetrol®)
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 (Ezetrol®)
Description: ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2(Lipitor®, Ezetrol®)
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 (Lipitor®)
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3(Lipitor®, Ezetrol®)
Description: atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 (Lipitor®)
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 (Ezetrol®)
Description: After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 (Lipitor®)
Description: atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4(Lipitor®, Ezetrol®)
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 (Ezetrol®)
Description: After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 (Ezetrol®)
Description: ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 (Lipitor®)
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 (Lipitor®, Ezetrol®)
Description: After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6(Lipitor®, Ezetrol®)
Description: atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 (Ezetrol®)
Description: After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
Study NCT02288338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 (Lipitor®)
Description: After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
Study NCT04769011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Description: Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
Study NCT04769011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).